Literature DB >> 24793345

Can paraoxonase 1 polymorphisms (L55 M and Q192 R) protect children with type 1 diabetes against lipid abnormalities?

Ons Fekih1, Sonia Triki2, Ilhem Hellara2, Fadoua Neffati2, Jihen Rejeb3, Asma Ommezzine3, Slaheddine Chouchane4, Mohamed Neji Guediche4, Ali Bouslama3, Mohamed Fadhel Najjar2.   

Abstract

BACKGROUND: Only a few studies have focused on the possible modulatory role of paraoxonase 1 (PON1) polymorphisms in lipid profiles, especially in children and in adolescents with type 1 diabetes (T1D).
OBJECTIVE: We propose to study the association between PON1 polymorphisms (PON1-55 and PON1-192) and a lipid profile in a young Tunisian population with T1D.
METHODS: The study compared 122 children and adolescents with T1D with 97 controls. Genomic DNA was collected from 116 patients and 91 controls. Lipid parameters were determined by automated methods. PON1 activity was measured by a spectrophotometric method and genotyping of the PON1 gene was assessed by multiplex polymerase chain reaction followed by restriction fragment-length polymorphism.
RESULTS: A significant increase in total cholesterol, high-density lipoprotein-cholesterol, low-density lipoprotein-cholesterol (LDL-C), apolipoprotein B (ApoB), and lipoprotein (a) (Lp(a)) and a significant decrease in apolipoprotein A1 (ApoA1), ApoA1/ApoB ratio, and PON1 activity/HDL-C ratio were observed in children with T1D compared with controls. In the LLQR haplotype, the group with diabetes showed significantly higher values of total cholesterol, LDL-C, apoB, Lp(a), and apoA1/apoB ratio compared with the control group. Those with diabetes with the LLQQ haplotype showed a significant decrease in LDL-C and Lp(a) compared with controls (P < .0001).
CONCLUSION: PON1 polymorphisms (PON1-55 and PON1-192) seem to be involved in the altering the lipid profile in T1D. The LLQR haplotype provided an atherogenic lipid profile in children with T1D compared with controls. LLQQ haplotype seemed to have a protective effect against the increase in LDL-C and Lp(a) that are heavily involved in the development of cardiovascular diseases.
Copyright © 2014 National Lipid Association. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Cardiovascular risk; Lipid disorders; Paraoxonase 1 activity; Paraoxonase 1 polymorphisms; Type 1 diabetes

Mesh:

Substances:

Year:  2014        PMID: 24793345     DOI: 10.1016/j.jacl.2014.03.001

Source DB:  PubMed          Journal:  J Clin Lipidol        ISSN: 1876-4789            Impact factor:   4.766


  7 in total

1.  Genetic Determinants of Dyslipidemia in African-Based Populations: A Systematic Review.

Authors:  Jean Jacques Noubiap; Edith Pascale M Mato; Magellan Guewo-Fokeng; Arnaud D Kaze; Houssam Boulenouar; Ambroise Wonkam
Journal:  OMICS       Date:  2018-12

Review 2.  Emerging risk biomarkers in cardiovascular diseases and disorders.

Authors:  Ravi Kant Upadhyay
Journal:  J Lipids       Date:  2015-04-08

Review 3.  Emerging biomarkers for the detection of cardiovascular diseases.

Authors:  Sreenu Thupakula; Shiva Shankar Reddy Nimmala; Haritha Ravula; Sudhakar Chekuri; Raju Padiya
Journal:  Egypt Heart J       Date:  2022-10-20

4.  The association between paraoxonase 1 activity and the susceptibilities of diabetes mellitus, diabetic macroangiopathy and diabetic microangiopathy.

Authors:  Diling Wu; Chenfang Wu; Yanjun Zhong
Journal:  J Cell Mol Med       Date:  2018-07-07       Impact factor: 5.310

5.  Associations of the PON1 rs854560 polymorphism with plasma lipid levels: a meta-analysis.

Authors:  Zhi Luo; Shujin Li; Irfan Muhammad; Md Rezaul Karim; Yongyan Song
Journal:  Lipids Health Dis       Date:  2018-12-03       Impact factor: 3.876

6.  Correlation of Paraoxonase-1 with glycated hemoglobin and lipid profile among Sudanese diabetic patients.

Authors:  Ahmed M Ahmed
Journal:  Pak J Med Sci       Date:  2019 Jul-Aug       Impact factor: 1.088

7.  Integrative analyses of TEDDY Omics data reveal lipid metabolism abnormalities, increased intracellular ROS and heightened inflammation prior to autoimmunity for type 1 diabetes.

Authors:  Leandro Balzano-Nogueira; Ricardo Ramirez; Tatyana Zamkovaya; Jordan Dailey; Alexandria N Ardissone; Srikar Chamala; Joan Serrano-Quílez; Teresa Rubio; Michael J Haller; Patrick Concannon; Mark A Atkinson; Desmond A Schatz; Eric W Triplett; Ana Conesa
Journal:  Genome Biol       Date:  2021-01-21       Impact factor: 13.583

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.